Overview

A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects

Status:
Completed
Trial end date:
2019-12-23
Target enrollment:
Participant gender:
Summary
This is a first in human Phase 1 study in two parts with healthy volunteers receiving a single dose of PU AD in three small cohorts and a multiple ascending dose in two small cohorts.
Phase:
Phase 1
Details
Lead Sponsor:
Samus Therapeutics, Inc.